Minimally invasive esophagectomy for esophageal cancer in octogenarians. Clinical and oncological outcomes.

Q2 Medicine Journal of Buon Pub Date : 2020-01-01

Elias Sdralis, Spyridon Davakis, Athanasios Syllaios, Eustratia Mpaili, Bruno Lorenzi, Alexandros Charalabopoulos

{"title":"Minimally invasive esophagectomy for esophageal cancer in octogenarians. Clinical and oncological outcomes.","authors":"Elias Sdralis, Spyridon Davakis, Athanasios Syllaios, Eustratia Mpaili, Bruno Lorenzi, Alexandros Charalabopoulos","doi":"","DOIUrl":null,"url":null,"abstract":"Purpose: Studies on patients undergoing esophagectomy for esophageal cancer have shown that thoracic and abdominal surgery may be performed safely in patients without an uppermost age cut-off. The aim of this study was to evaluate the morbidity and mortality of radical minimally invasive esophagectomy for cancer in patients over 80 years old.Methods: A retrospective analysis of prospectively collected data over a period of 4 years was conducted. During the study period 184 esophagectomies were performed. A total of 12 octogenarians that underwent Minimally Invasive Esophagectomy (MIE) for cancer were included in the study. Our results were compared to the UK national outcomes as presented in the National Esophago-Gastric Cancer Audit (NOGCA) 2017 report.Results: Median overall survival (OS) was 16.5 months (range: 6-38) and progression-free survival (PFS) 14.5 months (tange:3-38). 30-and 90-day postoperative mortality was zero. Postoperative complications included chest infection (CI) in 4 (33.3%) patients, anastomotic leakage (AL) in 3 (25%) and atrial fibrillation in 2 (16.7%).Conclusions: MIE should therefore be considered as an effective treatment strategy even in elderly patients over 80 years of age.","PeriodicalId":50248,"journal":{"name":"Journal of Buon","volume":"25 1","pages":"520-526"},"PeriodicalIF":0.0000,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Buon","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: Studies on patients undergoing esophagectomy for esophageal cancer have shown that thoracic and abdominal surgery may be performed safely in patients without an uppermost age cut-off. The aim of this study was to evaluate the morbidity and mortality of radical minimally invasive esophagectomy for cancer in patients over 80 years old.

Methods: A retrospective analysis of prospectively collected data over a period of 4 years was conducted. During the study period 184 esophagectomies were performed. A total of 12 octogenarians that underwent Minimally Invasive Esophagectomy (MIE) for cancer were included in the study. Our results were compared to the UK national outcomes as presented in the National Esophago-Gastric Cancer Audit (NOGCA) 2017 report.

Results: Median overall survival (OS) was 16.5 months (range: 6-38) and progression-free survival (PFS) 14.5 months (tange:3-38). 30-and 90-day postoperative mortality was zero. Postoperative complications included chest infection (CI) in 4 (33.3%) patients, anastomotic leakage (AL) in 3 (25%) and atrial fibrillation in 2 (16.7%).

Conclusions: MIE should therefore be considered as an effective treatment strategy even in elderly patients over 80 years of age.

微信好友朋友圈 QQ好友复制链接

本刊更多论文

微创食管切除术治疗八十高龄食管癌。临床和肿瘤预后。

目的:对食管癌患者行食管癌切除术的研究表明，胸腹手术可以在没有最高年龄限制的患者中安全进行。本研究的目的是评估80岁以上癌症患者行根治性微创食管切除术的发病率和死亡率。方法:对前瞻性收集的4年资料进行回顾性分析。在研究期间，184例患者接受了食管切除术。共有12名因癌症接受微创食管切除术(MIE)的80多岁老人被纳入研究。我们的结果与2017年国家食管胃癌审计(NOGCA)报告中提出的英国国家结果进行了比较。结果:中位总生存期(OS)为16.5个月(范围:6-38)，无进展生存期(PFS)为14.5个月(范围:3-38)。术后30天和90天死亡率均为零。术后并发症包括4例(33.3%)胸腔感染，3例(25%)吻合口漏，2例(16.7%)心房颤动。结论:因此，即使在80岁以上的老年患者中，MIE也应被视为一种有效的治疗策略。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Journal of Buon 医学-肿瘤学

自引率

0.00%

发文量

审稿时长

4-8 weeks

期刊介绍： JBUON aims at the rapid diffusion of scientific knowledge in Oncology. Its character is multidisciplinary, therefore all aspects of oncologic activities are welcome including clinical research (medical oncology, radiation oncology, surgical oncology, nursing oncology, psycho-oncology, supportive care), as well as clinically-oriented basic and laboratory research, cancer epidemiology and social and ethical aspects of cancer. Experts of all these disciplines are included in the Editorial Board. With a rapidly increasing body of new discoveries in clinical therapeutics, the molecular mechanisms that contribute to carcinogenesis, advancements in accurate and early diagnosis etc, JBUON offers a free forum for clinicians and basic researchers to make known promptly their achievements around the world. With this aim JBUON accepts a broad spectrum of articles such as editorials, original articles, reviews, special articles, short communications, commentaries, letters to the editor and correspondence among authors and readers. JBUON keeps the characteristics of its former paper print edition and appears as a bimonthly e-published journal with continuous volume, issue and page numbers.